A hybrid scaffold is disclosed which is made of materials that define peripheral layers designed to interface with the tissues in the implant site and one or more intermediate layers. The materials are combined to give the scaffold mechanical properties suitable for withstanding the stresses of the implant site. The materials are fibroin for the peripheral layers and polyurethane combined with fibroin for each intermediate layer.

A spherical particle comprising decellularized omentum being between 1 nM-300 μM in diameter is disclosed. In some embodiments, the particle comprises biological cells. In other embodiments, the particle comprises a biomolecule. Uses of the particles are also disclosed.

A spherical particle comprising decellularized omentum being between 1 nM-300 μM in diameter is disclosed. In some embodiments, the particle comprises biological cells. In other embodiments, the particle comprises a biomolecule. Uses of the particles are also disclosed.

The method for decellularization of kidney tissue according to the present invention, the decellularized material produced through the method, and a bioink comprising the decellularized material have the effect of maximizing the effect of kidney treatment by maximizing the content of components specialized for kidney treatment such as the collecting duct and renal tubule of the kidney.

A system and method for decellularizing tissue is provided. The system includes a pretreatment chamber including a pretreatment solution (e.g., a surfactant), a decellularization solution comprising carbon dioxide and one or more polar solvents, as well as an environmental chamber comprising a treatment chamber. The environmental chamber is maintained at a temperature greater than 31.1° C. and the carbon dioxide is maintained at a pressure greater than 7.38 megapascals to form supercritical CO.sub.2. Tissue treated with the decellularization system and method can contain less than 0.05 micrograms of DNA per milligram of dry tissue after the tissue is exposed to the decellularization solution for a time period ranging from about 1 minute to about 2 hours with minimal ECM fiber disruption. A two-part decellularization solution comprising a surfactant as well as supercritical CO.sub.2 and one or more polar solvents is also provided.

The invention relates to a bioactive bone repair substrate comprising granules obtainable by or obtained from a set solid state mixture of a calcium phosphate based bone repair matrix and a bioactive material, preferably granules having an average diameter between 25 and 10,000 μm.

The present invention is directed to a composition comprising a matrix suitable for implantation in humans, comprising defatted, shredded, allogeneic human muscle tissue that has been combined with an aqueous carrier and dried in a predetermined shape. Also disclosed is a tissue graft or implant comprising a matrix suitable for implantation in humans, comprising defatted, shredded, allogeneic human muscle tissue that has been combined with an aqueous carrier and dried in a predetermined shape. The composition and/or tissue graft or implant of the invention is usable in combination with seeded cells, a tissue growth factor, and/or a chemotactic gent to attract a desired cell.

A notochordal cell matrix solution as a bioactive lubricant in the treatment of Osteoarthritis, more specifically for use as a bioactive lubricant in viscosupplementation. The notochordal cell matrix solution is capable of reducing the pain in osteoarthritic joints.

A bioprosthetic valve and a preparation method thereof are provided. The bioprosthetic valve includes a stent and a functional biological tissue material attached to the stent. The functional biological tissue material is a biologicaltissue covalently bonded with an active group and a functional molecule or group. The method improves the anti-thrombosis and anti-calcification functions by covalently modifying the surface of a biological valve using an active group and a functional molecule or group with a substantial degree of grafting. The new bioprosthetic valve does not include aldehyde residues, exhibits excellent biocompatibility, optimal mechanical properties, high stability, and can meet the performance requirements of a biological valve delivered through a catheter.

A prosthetic tissue valve and a method of treating the prosthetic tissue valve are provided. The method includes: decreasing a temperature of a chamber carrying the prosthetic tissue valve from a first preset temperature to a second preset temperature in a first cooling rate; decreasing the temperature of the chamber carrying the prosthetic tissue valve from the second preset temperature to a third preset temperature in a second cooling rate; and performing a drying process to the prosthetic tissue valve. The second preset temperature is a critical crystallization temperature and is greater than a crystallization temperature of the prosthetic tissue valve. The third preset temperature is lower than the crystallization temperature of the prosthetic tissue valve, and the second cooling rate is greater than the first cooling rate.